Treatment sequence in castration-resistant prostate cancer: A retrospective study in the new anti-androgen era

In recent years, abiraterone acetate (AA) and enzalutamide (EZL) have become available for the treatment of cancer. Prior clinical trials have demonstrated the benefits of these agents in males with castration-resistant prostate cancer (CRPC). The optimal sequencing of available therapies in the con...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Mol Clin Oncol
Autors principals: Hoshi, Senji, Numahata, Kenji, Ono, Kunio, Yasuno, Nobuhiro, Bilim, Vladimir, Hoshi, Kiyotsugu, Amemiya, Hiroshi, Sasagawa, Isoji, Ohta, Shoichiro
Format: Artigo
Idioma:Inglês
Publicat: D.A. Spandidos 2017
Matèries:
Articles
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5574190/
https://ncbi.nlm.nih.gov/pubmed/28855993
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/mco.2017.1361
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars